Committed to Making a Difference in Patients’ Lives
Ascendis Pharma is applying our innovative TransConTM technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, endocrinology rare disease product candidates in clinical development, and multiple preclinical programs in oncology, our second therapeutic area.
ACcomplisH Now Initiated
ACcomplisH is a global phase 2 clinical trial designed to evaluate TransCon CNP in children with achondroplasia (ACH). Learn More
TransCon Technology Platform
Learn how we’re using our innovative TransCon technology (refers to “transient conjugation”) to create best-in-class products to address unmet patient needs.